Abstract: Systems and methods for convergent 3D displays. In one embodiment, the 3D display has a display screen that includes a convergent reflector and a horizontally narrow angle diffuser. The convergent reflector focuses 2D images projected on the diffuser from an array of 2D image projectors to form viewpoints in an eyebox where one viewpoint corresponds to one projector. At a particular viewpoint, the viewer's eye sees a full-screen field of view from a corresponding projector in the array. The narrow angle diffuser diffuses incident rays projected from the 2D image projectors into narrow angular slices so that the views in the eyebox are continuously blended together. The system and methods provide advantages in that only a few projectors are required in the array to provide the viewer with a full-screen field of view and a sufficiently large eyebox for comfortable viewing.

Abstract: Systems and methods for calibrating a 3D display system. In one embodiment, a system includes a display screen, 2D image projectors that project 2D projection images onto the screen and a camera that captures calibration images of the screen. A computer generates the 2D projection images, which include calibration patterns, and processes the captured calibration images. The computer uses the calibration images to calculate corrections based upon the calibration images. The computer can then generate corrected 2D projection images that are projected by the 2D image projectors onto the screen to produce a substantially visually correct 3D image with continuous viewing, true horizontal parallax, and a different view for each eye within a valid viewing zone. The corrections to the images may include corrections to the geometry (including distortion, alignment, etc.) color (including intensity and related parameters).

Abstract: Systems and methods for convergent 3D displays. In one embodiment, the 3D display has a display screen that includes a convergent reflector and a horizontally narrow angle diffuser. The convergent reflector focuses 2D images projected on the diffuser from an array of 2D image projectors to form viewpoints in an eyebox where one viewpoint corresponds to one projector. At a particular viewpoint, the viewer's eye sees a full-screen field of view from a corresponding projector in the array. The narrow angle diffuser diffuses incident rays projected from the 2D image projectors into narrow angular slices so that the views in the eyebox are continuously blended together. The system and methods provide advantages in that only a few projectors are required in the array to provide the viewer with a full-screen field of view and a sufficiently large eyebox for comfortable viewing.

Abstract: Systems and methods for calibrating a 3D display system. In one embodiment, a system includes a display screen, 2D image projectors that project 2D projection images onto the screen and a camera that captures calibration images of the screen. A computer generates the 2D projection images, which include calibration patterns, and processes the captured calibration images. The computer uses the calibration images to calculate corrections based upon the calibration images. The computer can then generate corrected 2D projection images that are projected by the 2D image projectors onto the screen to produce a substantially visually correct 3D image with continuous viewing, true horizontal parallax, and a different view for each eye within a valid viewing zone. The corrections to the images may include corrections to the geometry (including distortion, alignment, etc.) color (including intensity and related parameters).

Abstract: The present invention provides a method of detecting and diagnosing pre-invasive breast cancer by identifying differentially expressed genes in early, pre-invasive breast cancer tissue. Differentially expressed genes can be used as genetic markers to indicate the presence of pre-invasive cancerous tissues. Microscopically-directed tissue sampling techniques combined with differential display or differential screening of cDNA libraries are used to determine differential expression of genes in the early stages of breast cancer. Differential expression of genes in preinvasive breast cancer tissue is confirmed by RT-PCR, nuclease protection assays and in-situ hybridization of ductal carcinoma in situ tissue RNA and control tissue RNA. The present invention also provides a method of screening for compounds that induce expression of the BRCA1 gene, whose product negatively regulates cell growth in both normal and malignant mammary epithlial cells.

Abstract: Genetic analysis of familial breast and ovarian cancer indicates that BRCA1 is a tumor suppressor gene. The BRCA1 gene encodes a 190 kDa protein with sequence homology and biochemical analogy to the granin family of proteins. Granins are secreted from endocrine cells via the regulated secretory pathway and are proteolytically cleaved to yield biologically active peptides. BRCA1 protein localizes to secretory vesicles, and was demonstrated to be secreted. Gene transfer of BRCA1 inhibits growth and tumorigenesis of breast and ovarian cancer cells, but not colon or lung cancer cells or fibroblasts, suggesting that BRCA1 encodes a tissue-specific growth inhibitor. Thus, BRCA1 is a secreted growth inhibitor and functions by a mechanism not previously described for tumor suppressor genes. The BRCA2 breast and ovarian cancer gene encodes a protein that also includes a granin region, indicating that the BRCA2 protein is also a secreted tumor suppressor.

Abstract: Genetic analysis of familial breast and ovarian cancer indicates that BRCA1 is a tumor suppressor gene. The BRCA1 gene encodes a 190 kDa protein with sequence homology and biochemical analogy to the granin family of proteins. Granins are secreted from endocrine cells via the regulated secretory pathway and are proteolytically cleaved to yield biologically active peptides. BRCA1 protein localizes to secretory vesicles, and was demonstrated to be secreted. Gene transfer of BRCA1 inhibits growth and tumorigenesis of breast and ovarian cancer cells, but not colon or lung cancer cells or fibroblasts, suggesting that BRCA1 encodes a tissue-specific growth inhibitor. Thus, BRCA1 is a secreted growth inhibitor and functions by a mechanism not previously described for tumor suppressor genes. The BRCA2 breast and ovarian cancer gene encodes a protein that also includes a granin region, indicating that the BRCA2 protein is also a secreted tumor suppressor.

Abstract: The present invention provides a method of detecting and diagnosing pre-invasive breast cancer by identifying differentially expressed genes in early, pre-invasive breast cancer tissue. Differentially expressed genes can be used as genetic markers to indicate the presence of pre-invasive cancerous tissues. Microscopically-directed tissue sampling techniques combined with differential display or differential screening of cDNA libraries are used to determine differential expression of genes in the early stages of breast cancer. Differential expression of genes in preinvasive breast cancer tissue is confirmed by RT-PCR, nuclease protection assays and in-situ hybridization of ductal carcinoma in situ tissue RNA and control tissue RNA.